AusBiotech submission re: tax impediments for small business
27 May, 2014AusBiotech has made a submission to the Board of Taxation, which is conducting a review to identify features in the tax system that are hindering or preventing small businesses from reaching their commercial goals.
ATP Innovations named incubator of the year
27 May, 2014 by Dylan Bushell-EmblingSydney life science and ICT business incubator ATP Innovations has won the Incubator of the Year Award at the NBIA's 2014 International Conference.
FDA knocks back QRxPharma's third Moxduo NDA
26 May, 2014 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) has, as expected, received a third Complete Response Letter from the US FDA covering a New Drug Application for pain drug Moxduo.
ResMed refines APAP therapy for women
23 May, 2014 by Dylan Bushell-EmblingResMed (ASX:RMD) has presented research into a new algorithm for providing APAP therapy that has been customised to reflect the distinct symptoms of female sleep apnoea patients.
Nasal devices improve breathing
23 May, 2014 by Susan WilliamsonPositive results for Rhinomed’s sport and respiratory technology, Turbine, will be followed later this year with the release of its first products targeting snoring and sleep quality.
Clinuvel gets orphan status for Scenesse in US too
22 May, 2014 by Dylan Bushell-EmblingClinuvel (ASX:CUV) has in one week been granted orphan status for its Scenesse drug in Hailey-Hailey disease in both the US and the EU.
Commercialisation Australia closes for new applications
22 May, 2014Commercialisation Australia (CA) is now closed for new applications, following the announcement in last week's federal Budget that it will cease from 1 January 2015 and the funds will be rolled into the new Entrepreneurs' Infrastructure Program (EIP).
Immuron signs SK distribution deal for Travelan
22 May, 2014 by Dylan Bushell-EmblingDB Pharm Korea has signed a deal giving it exclusive rights to distribute Immuron's (ASX:IMC) travellers' diarrhoea treatment Travelan in South Korea.
Phosphagenics' opioid patch eases pain in horses
21 May, 2014 by Dylan Bushell-EmblingAll six injured thoroughbred racehorses treated with Phosphagenics' TPM/oxycodone patch during a pilot trial recovered from pain within 48 hours.
Avita appoints new chairman
20 May, 2014 by Dylan Bushell-EmblingLou Panaccio, an executive with more than 30 years of healthcare and life science experience, has joined the board of Avita Medical (ASX:AVH) as its chairman.
Research Australia Awards 2014 open for nominations
20 May, 2014The Research Australia Awards 2014 are calling for nominations of those making an impact early in their research career; those constantly advocating for health and medical research; philanthropic heroes; and exceptional leaders and pioneers.
Clinuvel gets orphan status for Scenesse in HHD
20 May, 2014 by Dylan Bushell-EmblingClinuvel (ASX:CUV) has received EMA orphan drug designation for Scenesse in Hailey-Hailey Disease, and has revealed it expects the agency to complete its review of the product in EPP by October.
Phylogica hit with two market setbacks
19 May, 2014 by Dylan Bushell-EmblingPhylogica's (ASX:PYC) research partner Janssen Pharmaceuticals has elected not to license the outcome of their collaboration and a Phylogica licensee has filed for bankruptcy.
GI Dynamics' EndoBarrier reduces need for insulin
16 May, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) said Australian type 2 diabetes patients treated with its EndoBarrier therapy were able to reduce or eliminate insulin therapy.
Bruising Budget strengthens resolve
15 May, 2014The biotech sector is regrouping after the bruising Federal Budget on Tuesday night delivered a round of cuts for biotechnology, including measures to reduce the R&D Tax Incentive and abolish the Innovation Investment Fund (IIF) and Commercialisation Australia (CA).
